

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3920151

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PEPLIN IRELAND LTD	04/15/2011
RECEIVING PARTY DATA	
Name:	AKTIESELSKABET AF 30. APRIL 2003
Street Address:	INDUSTRI PARKEN 55
City:	BALLERUP
State/Country:	DENMARK
Postal Code:	2700
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15163410
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(212) 641-2279
Email:	mwhite@fr.com
Correspondent Name:	TONY ZHANG
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	42764-0004011
NAME OF SUBMITTER:	MARYANN WHITE
SIGNATURE:	/Maryann White/
DATE SIGNED:	06/15/2016
Total Attachments: 19	
source=Assignment Peplin Ireland Aktieselskabet#page1.tif	
source=Assignment Peplin Ireland Aktieselskabet#page2.tif	
source=Assignment Peplin Ireland Aktieselskabet#page3.tif	
source=Assignment Peplin Ireland Aktieselskabet#page4.tif	
source=Assignment Peplin Ireland Aktieselskabet#page5.tif	

source=Assignment Peplin Ireland Aktieselskabet#page6.tif
source=Assignment Peplin Ireland Aktieselskabet#page7.tif
source=Assignment Peplin Ireland Aktieselskabet#page8.tif
source=Assignment Peplin Ireland Aktieselskabet#page9.tif
source=Assignment Peplin Ireland Aktieselskabet#page10.tif
source=Assignment Peplin Ireland Aktieselskabet#page11.tif
source=Assignment Peplin Ireland Aktieselskabet#page12.tif
source=Assignment Peplin Ireland Aktieselskabet#page13.tif
source=Assignment Peplin Ireland Aktieselskabet#page14.tif
source=Assignment Peplin Ireland Aktieselskabet#page15.tif
source=Assignment Peplin Ireland Aktieselskabet#page16.tif
source=Assignment Peplin Ireland Aktieselskabet#page17.tif
source=Assignment Peplin Ireland Aktieselskabet#page18.tif
source=Assignment Peplin Ireland Aktieselskabet#page19.tif

FINAL
15 April 2011

DATED 15th April 2011

PEPLIN IRELAND LIMITED

Assignor

and

AKTIESELSKABET AF 30. APRIL 2003

Assignee

DEED OF ASSIGNMENT

A&L Goodbody

FINAL

TABLE OF CONTENTS

1. Interpretation..... 2
2. Assignment..... 3
3. CONSIDERATION..... 4
4. WARRANTIES..... 4
5. VAT & TAX..... 4
6. Further Assurance..... 5
7. Waiver..... 5
8. Entire Agreement..... 5
9. Variation..... 5
10. Severance..... 5
11. Counterparts..... 6
12. Notices..... 6
13. Governing Law and Jurisdiction..... 6
Schedule 1..... 6
Schedule 2..... 6

FINAL

FINAL 15 April 2011

THIS AGREEMENT is dated 15th April 2011

BETWEEN:

1. PEPLIN IRELAND Ltd. a private limited company incorporated in Ireland (registered number 442362) having its registered office at One Spencer Dock, North Wall Quay, Dublin 1, Ireland (Assignor); and
2. AKTIESELSKABET AF 30. APRIL 2003 Incorporated and registered in Denmark with company number 27159133 whose registered office is at Industriparken 55, 2700 Ballerup, Denmark (Assignee).

RECITALS:

1. The Assignor has certain rights in the Patents (as defined below) pursuant to the Intellectual Property License dated 26 June 2007 entered into between Peplin Research Pty. Ltd. (as trustee of the Peplin Unit Trust) and Peplin Ireland Ltd.
2. The Assignor has agreed to assign all of its rights referred to at (A) above to the Assignee on the terms set out in this Deed of Assignment.

IT IS AGREED:

1. INTERPRETATION

- 1.1. The definitions and rules of interpretation in this clause apply in this agreement.

Assigned Rights means all of the Assignor's rights pertaining to the Patents granted under the Head Licence.

Business Day means any day on which banks are generally open for business in Dublin, excluding Saturdays and Sundays.

Effective Date means 1 January 2011.

Head Licence means the contract described in Schedule 1.

Patents mean the patents and the applications the particulars of which are set out in Schedule 2.

VAT means the value added tax imposed in any member state of the European Union pursuant to Council Directive (EC) 2006/112 on the common system of value added tax and national legislation implementing that Directive or any predecessor to it, or supplemental to that Directive, or any similar tax which may be substituted for or levied in addition to it or any value added, sales, turnover or similar tax imposed in any country that is not a member of the European Union.

- 1.2. Clause and schedule headings shall not affect the interpretation of this agreement.

FINAL

- 1.3. The schedules form part of this agreement and shall have effect as if set out in full in the body of this agreement. Any reference to this agreement includes the Schedules.
- 1.4. References to clauses and schedules are to the clauses and schedules of this agreement.
- 1.5. Unless the context otherwise requires, words in the singular include the plural and in the plural include the singular.
- 1.6. Unless the context otherwise requires, a reference to one gender shall include a reference to the other genders.
- 1.7. A reference to a statute or statutory provision is a reference to it as amended, extended or re-enacted from time to time provided that, as between the parties, no such amendment, extension or re-enactment shall apply for the purposes of this agreement to the extent that it would impose any new or extended obligation, liability or restriction on, or otherwise adversely affect the rights of, any party. This clause does not, however, apply in relation to taxation.
- 1.8. A reference to a statute or statutory provision shall include any subordinate legislation made from time to time under that statute or statutory provision.
- 1.9. Writing or written includes faxes but not e-mail.
- 1.10. Any words following the terms including, includes, in particular or any similar expression shall be construed as illustrative and shall not limit the sense of the words, description, definition, phrase or term preceding those terms.
- 1.11. A person includes a natural person, corporate or unincorporated body (whether or not having separate legal personality) and that person's legal and personal representatives, successors and permitted assigns.

2. ASSIGNMENT

- 2.1. In consideration of (the "Consideration")
 - 2.1.1. the Assignor assigns and transfers all of its rights, obligations, title, interest and benefit in and to the Assigned Rights to the Assignee, including the royalty obligations vested in the Assignor in clause 3.1 (b) of the Head License. The Assignee shall enjoy all the rights and benefits of the Assignor and shall perform all the Assignor's obligations in respect of the Assigned Rights, and all references to the Assignor in the Assigned Rights shall be read and construed as references to the Assignee; and
 - 2.1.2. the Assigned Rights shall be deemed to have transferred in accordance with the provisions of this Deed of Assignment as of the Effective Date. The transfer of the Assigned Rights occurs immediately upon execution of this Deed of Assignment. However, the parties agree that as between themselves the parties will treat the transfer as having occurred on The Effective Date is 1 January 2011.

FINAL

4. **WARRANTIES**

4.1. The Assignor warrants that it:

- 4.1.1. has authority to enter into this Deed of Assignment and to assign the Assigned Rights in accordance with the provisions of this Deed of Assignment;
- 4.1.2. has not assigned or otherwise transferred any of the Assigned Rights to any other person or entity; and
- 4.1.3. the Assigned Rights are not subject to any mortgage, pledge, lien, charge or other encumbrance.

6. **FURTHER ASSURANCE**

The Assignor shall, at the Assignor's cost, perform (or procure the performance of) all further reasonable acts and things, and execute and deliver or procure the execution or delivery of all further documents, required by law or which the Assignee reasonably requests, to vest in the Assignee the full benefit of the right, title and interest assigned to the Assignee under this Deed of Assignment.

8. **ENTIRE AGREEMENT**

8.1. This agreement constitutes the whole agreement between the parties and supersedes all previous agreements between the parties relating to its subject matter.

9. **VARIATION**

No variation of this agreement shall be effective unless it is in writing and signed by the parties (or their authorised representatives).

11. **COUNTERPARTS**

This Agreement may be executed in any number of counterparts, and by the several parties to it on separate counterparts, each of which when so executed will constitute an original but all of which together will evidence the same agreement.

IN WITNESS whereof this agreement has been duly executed as a deed by the parties on the date set out at the beginning of this Agreement.

FINAL

SCHEDULE 1

HEAD LICENCE

**INTELLECTUAL PROPERTY LICENSE DATED 29 JUNE 2007 ENTERED INTO BETWEEN PEPLIN
RESEARCH PTY LTD (AS TRUSTEE OF THE PEPLIN UNIT TRUST) AND PEPLIN IRELAND
LIMITED.**

FINAL

**PATENT
REEL: 038923 FRAME: 0424**

SCHEDULE 2

PATENTS

Patent Title	Country	Application No.	Filing Date	Patent No.	Grant Date	Status
Anti-cancer compounds	Australia	87217/88	10-Aug-88	736230	08-Nov-01	Granted
Anti-cancer compounds - I	Australia	48118/01	30-May-01	750024	07-Nov-02	Granted
Anti-cancer compounds - II	Australia	48117/01	30-May-01	748548	19-Sep-02	Granted
Anti-cancer compounds - III	Australia	48118/01	30-May-01	750028	07-Nov-02	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Austria	n/a	19-Aug-88	1015413	04-Jun-88	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Belgium	n/a	19-Aug-88	1015413	04-Jun-88	Granted
Compounds present in plants, composition comprising a compound, method of treatment of cancer, method of inhibiting and stimulating the activity of neoplastic cells, method of preventing or alleviating damage to the skin and use of a compound and composition	Brazil	PI0811327.5	19-Aug-88			Under examination - prosecution suspended
Anti-cancer compounds	Canada	2301082	19-Aug-88	2301082	03-Feb-89	Granted
Anti-cancer compounds	China	88807751.5	19-Aug-88			Under examination
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Cyprus	n/a	19-Aug-88	1015413	04-Jun-88	Granted
Use of an ingenane compound for the manufacture of a	Denmark	n/a	19-Aug-88	1015413	04-Jun-88	Granted

FINAL

Patent Title	Country	Application No.	Filing Date	Patent No.	Patent Date	Status
medicament for the treatment of cancer						
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Europe	85938534.6	19-Aug-88	1015413	04-Jun-89	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Finland	n/a	19-Aug-88	1015413	04-Jun-89	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	France	n/a	19-Aug-88	1015413	04-Jun-89	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Germany	69839566.7	19-Aug-88	1015413	04-Jun-89	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Greece	n/a	19-Aug-88	1015413	04-Jun-89	Granted
Anti-cancer compounds	Hungary	P0004262	19-Aug-88			Under examination
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Ireland	n/a	19-Aug-88	1015413	04-Jun-89	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Italy	n/a	19-Aug-88	1015413	04-Jun-89	Granted
Anti-cancer compounds	Japan	2880-208321	19-Aug-88			Under examination
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Luxembourg	n/a	19-Aug-88	1015413	04-Jun-89	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Monaco	n/a	19-Aug-88	1015413	04-Jun-89	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Netherlands	n/a	19-Aug-88	1015413	04-Jun-89	Granted
Use of an ingenane	Portugal		19-Aug-88	1015413	04-Jun-89	Granted

FINAL

Patent Title	Country	Application No.	Filing Date	Publ. No.	Patent Date	Status
compound for the manufacture of a medicament for the treatment of cancer						
Anti-cancer compounds	Singapore	200000202.4	19-Aug-99	71228	12-Mar-02	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Spain	n/a	19-Aug-98	1016413	04-Jun-03	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Sweden	n/a	19-Aug-98	1016413	04-Jun-03	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Switzerland	n/a	19-Aug-98	1016413	04-Jun-03	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	United Kingdom	n/a	19-Aug-98	1016413	04-Jun-03	Granted
Anti-cancer compounds	USA	09/406190	13-Aug-99	6432462	13-Aug-03	Granted
Anti-cancer compounds	USA	00/055178	21-Jun-01	6737181	07-Sep-04	Granted
Methods for stimulating the immune system	USA	09/036997	21-Jun-01	6944013	18-Jan-06	Granted
Anti-cancer compounds	USA	10/506611	22-Jul-04	7410059	12-Aug-08	Granted
Therapeutic agents - I	Australia	83861/01	07-Jun-01	762462	23-Jan-03	Granted
Methods for the treatment or prophylaxis of an inflammatory condition and for the immunoprotection of a subject, composition, computer program product, process for separating macrocyclic diterpenes from a biomass and use of a derivative or chemical analogue thereof	Brazil	PI0111423.9	07-Jun-01			Pending - request for examination filed
Therapeutic agents - I	Canada	2411840	07-Jun-01			Under examination
Therapeutic agents - I	Europe (designating AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)	01937072.8	07-Jun-01			Under examination
Therapeutic agents - I	Japan	2003-601455	07-Jun-01			Pending - request for examination

FINAL

Patent Title	Country	Application No.	Filing Date	Patent No.	Patent Date	Status
						Filed
Therapeutic agents - I	New Zealand	622426	07-Jun-01	622426	09-Sep-04	Granted
Therapeutic agents - I	USA	10/315280	07-Jun-01	7448492	11-Nov-08	Granted
Therapeutic agents - II	Australia	63602/01	07-Jun-01	752436	23-Jan-03	Granted
A method for the treatment or prophylaxis of an inflammatory condition, of immunoprotection and immunopotential of a subject, a composition, a computer and a computer program product	Brazil	PI0111458.1	07-Jun-01			Pending - request for examination filed
Therapeutic agents - II	Canada	2411680	07-Jun-01			Under examination filed
Therapeutic agents - II	Europe (designating AT, SE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)	01037873.6	07-Jun-01			Under examination
Therapeutic agents - II	Japan	2002-501466	07-Jun-01			Pending - request for examination filed
Therapeutic agents - II	New Zealand	622426	07-Jun-01	622426	09-Sep-04	Granted
Macrocyclic diuretics for treating conditions associated with protein kinase C	USA	10/315318	07-Jun-01			Accepted
Macrocyclic diuretics for treating conditions associated with protein kinase C	USA	12/643,087	16-Aug-09			Pending
Therapeutic agents - III	Australia	7373201	07-Jun-01	748542	18-Sep-02	Granted
Methods for the treatment or prophylaxis of condition or disorder related to PKC, for modulating the expression of genetic sequence and for stimulating the activation or function of a promoter, computer and computer program product	Brazil	PI0111575.5	07-Jun-01			Pending - request for examination filed

FINAL

Patent Title	Country	Application No.	Filing Date	Patent No.	Patent Date	Status
Therapeutic agents - III	Canada	2411726	07-Jun-01			Pending - request for examination filed
Therapeutic agents - III	Europe (designating AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)	01940015.8	07-Jun-01			Under examination
Therapeutic agents - III	Japan	2002-501454	07-Jun-01			Pending - request for examination filed
Therapeutic agents - III	New Zealand	522427	07-Jun-01	522427	08-Sep-04	Granted
Treatment of prostate cancer	Australia	79493/01	07-Aug-01	764776	06-Mar-03	Granted
Treatment of prostate cancer	Canada	2416764	07-Aug-01			Under examination
Treatment of prostate cancer	Europe (designating AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)	01957628.8	07-Aug-01			Under examination
Treatment of prostate cancer	Japan	2002-517978	07-Aug-01			Pending - request for examination filed
Treatment of prostate cancer	New Zealand	624062	07-Aug-01	624062	11-Nov-04	Granted
Treatment of prostate cancer	USA	11/324507	03-Jan-06	7376446	27-May-08	Granted
Treatment of solid cancers	Australia	2005316186	02-Dec-05			Pending - request for examination filed
Treatment of solid cancers	Canada	2589802	02-Dec-05			Pending - request for examination due 02-Dec-10
Treatment of solid cancers	Europe (designating AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)	06813582.3	02-Dec-05			Pending - request for examination filed

FINAL

Patent Title	Country	Application No.	Filing Date	Patent No.	Patent Date	Status
Treatment of solid cancers	New Zealand	504710	02-Dec-05			Accepted
Treatment of solid cancers	New Zealand	593157	05-Feb-10			Under examination
Treatment of solid cancers	USA	11792284	02-Dec-05			Under examination
Methods for wound healing	Australia	2006317623	25-Nov-08			Pending - request for examination filed
Methods for wound healing	Brazil	P0618926.1	25-Nov-08			Pending - request for examination filed
Methods for wound healing	Canada	2628890	25-Nov-08			Pending - request for examination due 24-Nov-11
Methods for wound healing	China	200880051833.8	25-Nov-08			Pending - request for examination filed
Methods for wound healing	Europe (designating AT, BE, GB, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)	08817537.1	25-Nov-08			Under examination
Methods for wound healing	Indonesia	W-09280801866	25-Nov-08			Pending - request for examination filed
Methods for wound healing	Japan	2008-541550	25-Nov-08			Pending - request for examination filed
Methods for wound healing	New Zealand	566168	25-Nov-08			Under examination
Methods for wound healing	Philippines	1-2008-591188	25-Nov-08			Pending
Methods for wound healing	Singapore	200853585.1	25-Nov-08			Under examination
Methods for wound healing	South Korea	10-2008-7014376	25-Nov-08			Pending - request for examination due 25-Nov-11
Methods for wound healing	USA	12894.713	25-Nov-08			Pending

FINAL

Patent Title	Country	Application No.	Filing Date	Patent No.	Patent Date	Status
Methods for wound healing	Vietnam	1-2006-01554	26-Nov-06			Under examination
Therapeutic formulations comprising ingenol-3-angelate	Australia	2006325244	18-Dec-06			Pending - request for examination filed
Therapeutic formulations	Brazil	PI0619918.4	18-Dec-06			Pending - request for examination filed
Therapeutic formulations comprising ingenol-3-angelate	Canada	2634073	18-Dec-06			Pending - request for examination due 18-Dec-11
Therapeutic formulations comprising ingenol-3-angelate	Egypt	200670063	18-Dec-06			Under examination
Therapeutic formulations comprising ingenol-3-angelate	Europe (designating AT, BE, BG, CY, CZ, DK, EE, FI, FR, GE, GR, HU, IS, IT, LV, LT, LU, MC, NL, PO, PT, IE, RO, SK, SI, ES, SE, CH, TR, GB, AL, BA, HR, MG, RS, Kosovo)	06929551.6	18-Dec-06			Under examination
Therapeutic formulations	India	6887DEL/N/2006	18-Dec-06			Pending - request for examination filed
Therapeutic formulations comprising ingenol-3-angelate	Israel	102221	18-Dec-06			Under examination
Therapeutic formulations comprising ingenol-3-angelate	Japan	2006-546103	18-Dec-06			Pending - request for examination filed
Therapeutic formulations	Mexico	MX/2006/007885	18-Dec-06			Pending
Therapeutic formulations	New Zealand	560197	18-Dec-06			Under examination
Therapeutic formulations comprising ingenol-3-angelate	Norway	20060150	18-Dec-06			Pending
Therapeutic formulations comprising ingenol-3-angelate	Singapore	20064464.6	18-Dec-06			Accepted
Therapeutic formulations	South Korea	10-2006-7017264	18-Dec-06			Pending - request for examination due 18-Dec-11

FINAL

Patent Title	Country	Application No.	Filing Date	Patent No.	Patent Date	Status
Therapeutic formulations comprising Ingenol-3-angelate	South Africa	2008/5137	16-Dec-08	2008/05137	29-Apr-09	Granted
Therapeutic formulations comprising Ingenol-3-angelate	USA	12/097255	16-Dec-08			Under examination
Therapeutic formulations	Vietnam	1-2008-01554	16-Dec-08			Pending
Treatment of virally induced lesions	Australia	2008243705	30-Apr-08			Pending
Treatment of virally induced lesions	Brazil	PI0810898.4	30-Apr-08			Pending
Treatment of virally induced lesions	Canada	266473	30-Apr-08			Pending
Treatment of virally induced lesions	China	200880019613.2	30-Apr-08			Pending
Treatment of virally induced lesions	Europe (designating AT, BE, BG, CH/LI, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, NO, PO, PT, RO, SE, SI, SK, TR, Bosnia-Herzegovina, Croatia, Kosovo, Macedonia, Montenegro, Serbia)	057334223	30-Apr-08			Pending
Treatment of virally induced lesions	Hong Kong	10103512.3	19-Mar-10			Pending
Treatment of virally induced lesions	Indonesia	W-00280303038	30-Apr-08			Pending
Treatment of virally induced lesions	Israel	201795	30-Apr-08			Pending
Treatment of virally induced lesions	Japan	2010-504381	30-Apr-08			Pending
Treatment of virally induced lesions	Malaysia	P120094567	30-Apr-08			Pending
Treatment of virally induced lesions	Mexico	MX/a/2008/011905	30-Apr-08			Pending
Treatment of virally induced lesions	New Zealand	580702	30-Apr-08			Pending
Treatment of virally induced lesions	Philippines	1-2009-502059	30-Apr-08			Pending
Treatment of virally induced lesions	Russian Federation	2008144100	30-Apr-08			Under examination
Treatment of virally induced lesions	Singapore	200807154-B	30-Apr-08			Pending
Treatment of virally induced lesions	South Africa	2008/07574	30-Apr-08			Pending

FINAL


Patent Title	Country	Application No.	Filing Date	Patent No.	Patent Date	Status
Treatment of virally induced lesions	South Korea	10-2009-7024661	30-Apr-08			Pending
Treatment of virally induced lesions	Ukraine	200912120	30-Apr-08			Pending
Treatment of virally induced lesions	USA	12/898,102	30-Apr-08			Pending
Treatment of virally induced lesions	Vietnam	1-2008-03622	30-Apr-08			Under examination
Skin treatment	International	PCT/AU2010/060162	12-Feb-10			Pending - Demand due 13-Dec-10 N/P due 13-Aug-11

Neostil/Osteoscreen portfolio


Patent family: inhibitors of proteasomal activity for stimulating bone and hair growth
Patent family: stimulation of hair growth by ginkgo biloba flavonoids

FINAL

GIVEN under the Common Seal of
Peplin Ireland Limited
affixed hereto and delivered as a Deed:



Witness Name



Glitte P. Aabo, Director



Witness Signature



Lars Olsen, Director

Signed by and on behalf of
Aktieselskabet af 30. April 2003
and delivered as a Deed:




Witness Name



Glitte P. Aabo, Chairman



Witness Signature



Nina Sølvér Hennings, Director

FINAL